The outcome of seven patients with hereditary tyrosinemia type 1
-
Songul Gokay
,
Pembe Soylu Ustkoyuncu
Abstract
Background:
Hereditary tyrosinemia type 1 (HT1) is a rare, inborn error of tyrosine metabolism. It is a fatal disorder without treatment. Early treatment may prevent acute liver failure, renal dysfunction, liver cirrhosis, hepatocellular carcinoma (HCC) and improves survival. The aim of the present study is to describe the clinical, biochemical, imaging and follow-up of seven patients with HT1 and to define the consequences of the late and interrupted treatment.
Methods:
A retrospective study was carried out with seven HT1 patients.
Results:
The median age at onset of clinical symptoms was 11.2 months (range, 3–28 months) and the median age at diagnosis was 22 months (range, 6–58 months). Liver enzymes and coagulation parameters were back to normal in all symptomatic patients in about 2 weeks. Alfa-fetoprotein (AFP) levels were normalized within the first year of therapy. Hypoechoic nodule formation was detected in two of the seven patients despite drug treatment without an increase of AFP and any dysplastic changes in the biopsies. One patient died due to metastatic HCC because of the late diagnosis and the poor compliance of the follow-up.
Conclusions:
This study showed once again that adherence to the treatment and a follow-up schedule of the patients are very important. Also it should not be forgotten that nodule formation can occur despite nitisinone treatment without an increase of AFP. Despite nitisinone treatment, HT1 patients still carry the risk of HCC. HCC must be detected before metastasis to other organs otherwise, patients may lose the chance for liver transplantation.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission. SG and MK designed the study. SG prepared the manuscript. SG, MK, FK and PSU provided clinical care to the patient.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Chakrapani A, Gissen P, McKiernan P. Disorders of tyrosine metabolism. In: Saudubray JM, van den Berghe G, Walter JH, editors. Inborn Metabolic Diseases, 5th ed. Heidelberg: Springer; 2012:265–76.10.1007/978-3-642-15720-2_18Suche in Google Scholar
2. Jorquera R, Tanguay RM. Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability. Hum Mol Genet 2001;10:1741–52.10.1093/hmg/10.17.1741Suche in Google Scholar
3. Mayorandan S, Meyer U, Gokcay G, Segarra NG, de Baulny HO, et al. Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice. Orphanet J Rare Dis 2014;9:107–23.10.1186/s13023-014-0107-7Suche in Google Scholar
4. Forget S, Patriquin HB, Dubois J, Lafortune M, Merouani A, et al. The kidney in children with tyrosinemia: sonographic, CT and biochemical findings. Pediatr Radiol 1999;29:104–8.10.1007/s002470050551Suche in Google Scholar
5. Sassa S, Kappas A. Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevulinic acid dehydratase activity by succinylacetone. J Clin Invest 1983;71:625–34.10.1172/JCI110809Suche in Google Scholar
6. Baumann U, Preece MA, Green A, Kelly DA, McKiernan PJ. Hyperinsulinism in tyrosinaemia type I. J Inherit Metab Dis 2005;28:131–5.10.1007/s10545-005-5517-1Suche in Google Scholar
7. Arora N, Stumper O, Wright J, Kelly DA, McKiernan PJ. Cardiomyopathy in tyrosinaemia type I is common but usually benign. J Inherit Metab Dis 2006;29:54–7.10.1007/s10545-006-0203-5Suche in Google Scholar
8. Kim SZ, Kupke KG, Ierardi-Curto L, Holme E, Greter J, et al. Hepatocellular carcinoma despite long-term survival in chronic tyrosinaemia I. J Inherit Metab Dis 2000;23:791–804.10.1023/A:1026756501669Suche in Google Scholar
9. Sander J, Janzen N, Peter M, Sander S, Steuerwald U, et al. Newborn screening for hepatorenal tyrosinemia: tandem mass spectrometric quantification of succinylacetone. Clin Chem 2006;52:482–7.10.1373/clinchem.2005.059790Suche in Google Scholar
10. Mustonen A, Ploos van Amstel HK, Berger R, Salo MK, Viinikka L, et al. Mutation analysis for prenatal diagnosis of hereditary tyrosinaemia type 1. Prenat Diagn 1997;17:964–6.10.1002/(SICI)1097-0223(199710)17:10<964::AID-PD164>3.0.CO;2-6Suche in Google Scholar
11. Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 1992;340:813–7.10.1016/0140-6736(92)92685-9Suche in Google Scholar
12. Holme E, Lindstedt S. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethyl-benzoyl)-1, 3-cyclohexanedione). J Inherit Metab Dis 1998;21:507–17.10.1023/A:1005410820201Suche in Google Scholar
13. Ozalp I, Coskun T, Tokol S, Demircin G, Mönch E. Inherited metabolic disorders in Turkey. J Inherit Metab Dis 1990;13:732–8.10.1007/BF01799576Suche in Google Scholar PubMed
14. Zeybek AC, Kiykim E, Soyucen E, Cansever S, Altay S, et al. Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience. Pediatr Int 2015;57:281–9.10.1111/ped.12503Suche in Google Scholar PubMed
15. Couce ML, Dalmau J, del Toro M, Pintos-Morell G, Aldámiz-Echevarría L. Spanish working group on tyrosinemia type 1. Tyrosinemia type 1 in Spain: mutational analysis, treatment and long-term outcome. Pediatr Int 2011;53:985–9.10.1111/j.1442-200X.2011.03427.xSuche in Google Scholar PubMed
16. El-Karaksy H, Fahmy M, El-Raziky M, El-Koofy N, El-Sayed R, et al. Hereditary tyrosinemia type 1 from a single center in Egypt: clinical study of 22 cases. World J Pediatr 2011;7:224–31.10.1007/s12519-011-0287-3Suche in Google Scholar PubMed
17. Arranz JA, Piñol F, Kozak L, Pérez-Cerdá C, Cormand B, et al. Splicing mutations, mainly IVS6-1(G>T), account for 70% of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patients. Hum Mutat 2002;20:180–8.10.1002/humu.10084Suche in Google Scholar PubMed
18. Jenkins J. Orphadin 2002 [Cited 30 December 2013.] Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/ 2002/21232lbl.pdf.10.1145/512526.512515Suche in Google Scholar
19. Masurel-Paulet A, Poggi-Bach J, Rolland MO, Bernard O, Guffon N, et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis 2008;31:81–7.10.1007/s10545-008-0793-1Suche in Google Scholar PubMed
20. van Spronsen FJ, Thomasse Y, Smit GP, Leonard JV, Clayton PT, et al. Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology 1994;20:1187–91.10.1002/hep.1840200513Suche in Google Scholar
21. van Spronsen FJ, Bijleveld CM, van Maldegem BT, Wijburg FA. Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro- methylbenzoyl)-1, 3-cyclohexanedione treatment. J Pediatr Gastroenterol Nutr 2005;40:90–3.10.1097/00005176-200501000-00017Suche in Google Scholar PubMed
22. Angileri F, Roy V, Morrow G, Scoazec JY, Gadot N, et al. Molecular changes associated with chronic liver damage and neoplastic lesions in a murine model of hereditary tyrosinemia type 1. Biochim Biophys Acta 2015;1852:2603–17.10.1016/j.bbadis.2015.09.002Suche in Google Scholar PubMed
23. Koelink CJ, van Hasselt P, van der Ploeg A, van den Heuvel-Eibrink MM, Wijburg FA, et al. Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer. Mol Genet Metab 2006;89:310–5.10.1016/j.ymgme.2006.07.009Suche in Google Scholar PubMed
24. van Ginkel WG, Gouw AS, van der Jagt EJ, de Jong KP, Verkade HJ, et al. Hepatocellular carcinoma in tyrosinemia type 1 without clear increase of AFP. Pediatrics 2015;135:749–52.10.1542/peds.2014-1913Suche in Google Scholar PubMed
25. Thimm E, Richter-Werkle R, Kamp G, Molke B, Herebian D, et al. Neurocognitive outcome in patients with hypertyrosinemia type 1 after long-term treatment with NTBC. J Inherit Metab Dis 2012;35:263–8.10.1007/s10545-011-9394-5Suche in Google Scholar PubMed
26. Bendadi F, de Koning TJ, Visser G, Prinsen HC, de Sain MG, et al. Impaired cognitive functioning in patients with tyrosinemia type 1 receiving nitisinone. J Pediatr 2014;164:398–4.10.1016/j.jpeds.2013.10.001Suche in Google Scholar PubMed
©2016 Walter de Gruyter GmbH, Berlin/Boston
Artikel in diesem Heft
- Frontmatter
- Review
- An update on thyroid-associated ophthalmopathy in children and adolescents
- Mini Review
- Systematic review and meta-analysis of the association between mumps during childhood and risk of type 1 diabetes mellitus
- Original Articles
- Glycemic variability predicts inflammation in adolescents with type 1 diabetes
- Prevalence and risk factors for diabetic retinopathy in a hospital-based population of Australian children and adolescents with type 1 diabetes
- One month of omega-3 fatty acid supplementation improves lipid profiles, glucose levels and blood pressure in overweight schoolchildren with metabolic syndrome
- The outcome of seven patients with hereditary tyrosinemia type 1
- Increased oxidative stress parameters in children with moderate iodine deficiency
- Relationship between 25(OH)D levels and circulating lipids in African American adolescents
- Endoglin and obestatin levels, cardiometabolic risk factors and subclinical atherosclerosis in children aged 10–18 years
- Lipoprotein-associated phospholipase A2 activity and low-density lipoprotein subfractions after a 2-year treatment with atorvastatin in adolescents with type 1 diabetes
- Genetic characteristics and long-term follow-up of 11 patients with congenital hyperinsulinism followed in a single center
- Pituitary volume in children with growth hormone deficiency, idiopathic short stature and controls
- Case Reports
- A novel insulin receptor mutation in an adolescent with acanthosis nigricans and hyperandrogenism
- Primary hyperparathyroidism may masquerade as rickets-osteomalacia in vitamin D replete children
- Co-existence of phenylketonuria either with maple syrup urine disease or Sandhoff disease in two patients from Iran: emphasizing the role of consanguinity
- Severe malnutrition causing superior mesenteric artery syndrome in an adolescent with Triple A syndrome
- Solving a case of allelic dropout in the GNPTAB gene: implications in the molecular diagnosis of mucolipidosis type III alpha/beta
Artikel in diesem Heft
- Frontmatter
- Review
- An update on thyroid-associated ophthalmopathy in children and adolescents
- Mini Review
- Systematic review and meta-analysis of the association between mumps during childhood and risk of type 1 diabetes mellitus
- Original Articles
- Glycemic variability predicts inflammation in adolescents with type 1 diabetes
- Prevalence and risk factors for diabetic retinopathy in a hospital-based population of Australian children and adolescents with type 1 diabetes
- One month of omega-3 fatty acid supplementation improves lipid profiles, glucose levels and blood pressure in overweight schoolchildren with metabolic syndrome
- The outcome of seven patients with hereditary tyrosinemia type 1
- Increased oxidative stress parameters in children with moderate iodine deficiency
- Relationship between 25(OH)D levels and circulating lipids in African American adolescents
- Endoglin and obestatin levels, cardiometabolic risk factors and subclinical atherosclerosis in children aged 10–18 years
- Lipoprotein-associated phospholipase A2 activity and low-density lipoprotein subfractions after a 2-year treatment with atorvastatin in adolescents with type 1 diabetes
- Genetic characteristics and long-term follow-up of 11 patients with congenital hyperinsulinism followed in a single center
- Pituitary volume in children with growth hormone deficiency, idiopathic short stature and controls
- Case Reports
- A novel insulin receptor mutation in an adolescent with acanthosis nigricans and hyperandrogenism
- Primary hyperparathyroidism may masquerade as rickets-osteomalacia in vitamin D replete children
- Co-existence of phenylketonuria either with maple syrup urine disease or Sandhoff disease in two patients from Iran: emphasizing the role of consanguinity
- Severe malnutrition causing superior mesenteric artery syndrome in an adolescent with Triple A syndrome
- Solving a case of allelic dropout in the GNPTAB gene: implications in the molecular diagnosis of mucolipidosis type III alpha/beta
